Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis

This is a prospective, multicenter, randomized controlled, open-label investigator-initiated clinical study to evaluate the clinical efficacy and quality of life of intrathecal chemotherapy through Ommaya reservoir in combination with systematic chemotherapy versus systemic chemotherapy alone in patients with Her-2 negative breast cancer with leptomeningeal metastasis.

Trial Details

NCT ID
NCT06230055
Phase
PHASE4
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • Ommaya reservoir
  • Systematic chemotherapy
  • Intrathecal chemotherapy
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Male or female aged 18 years or above;
  • Can understand the purpose of clinical trials and the benefits and risks, voluntarily participate in and sign the informed consent
  • The physical status score of the Eastern Oncology Consortium (ECOG) was ≤3;
  • HER2-metastatic breast cancer confirmed histologically or cytologically (HER2- is defined as either a standard immunohistochemical (IHC) test resul…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →